InvestorsHub Logo
Followers 35
Posts 6308
Boards Moderated 0
Alias Born 02/09/2015

Re: None

Friday, 09/25/2015 7:38:45 PM

Friday, September 25, 2015 7:38:45 PM

Post# of 403077
Ladies and gents, nota bene: you heard it here first. Jay Bradner will take over from Mark Fishman for Novartis Biomedical research. He works at Harvard Med and at Dana Farber and his publishing record includes many articles on topics you might guess incl epigenetics for example.

You wanna guess if he has heard about Kevetrin? I would bet he has. He is walking around the halls of Dana Farber and has to know Dr Shapiro

I would expect Novartis to have a serious interest in CTIX/K, IF IT WORKS.

This has to be god news for us.

We shall see!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News